Oxford University Press

SHERPA: Yellow

People

  1. De Angelis
    De Angelis
  2. Shuman
    Shuman
  3. Omuro
    Omuro
  4. Rosenblum
    Rosenblum
  5. Motzer
    Motzer
  6. Olson
    Olson
  7. Dunkel
    Dunkel
  8. Hudis
    Hudis
  9. Saltz
    Saltz
  10. Kaley
    Kaley

Groups

  1. Central Nervous System Disease Management Team (430)
  2. Population Sciences Research Program (346)
  3. Sloan Kettering Institute Faculty (297)
  4. Breast Cancer Disease Management Team (241)
  5. Melanoma Disease Management Team (211)
  6. Genitourinary Disease Management Team (188)
  7. Hepatopancreaticobiliary Disease Management Team (186)
  8. Biostatistics Service (183)
  9. Thoracic Malignancies Disease Management Team (182)
  10. Surgery (180)
Search Within
Refine Results
Formats
  1. Journal Article (1275)
  2. Meeting Abstract (792)
  3. Book Section (133)
  4. Book Whole (15)
  5. Conference Paper (2)
Groups
  1. Central Nervous System Disease Management Team (430)
  2. Population Sciences Research Program (346)
  3. Sloan Kettering Institute Faculty (297)
  4. Breast Cancer Disease Management Team (241)
  5. Melanoma Disease Management Team (211)
  6. Genitourinary Disease Management Team (188)

More Groups

People
  1. Lisa De Angelis (101)
  2. Stewart Shuman (67)
  3. Lauren Abrey (66)
  4. Antonio Omuro (62)
  5. Marc Rosenblum (52)
  6. Robert Motzer (46)

More People

Years
  1. 2018 (112)
  2. 2017 (258)
  3. 2016 (218)
  4. 2015 (143)
  5. 2014 (150)
  6. 2013 (111)

More Years

Publications
  1. Annals of Oncology (605)
  2. Neuro-Oncology (466)
  3. JNCI: Journal of the National Cancer Institute (255)
  4. Nucleic Acids Research (144)
  5. Clinical Infectious Diseases (89)
  6. American Journal of Clinical Pathology (53)

More Publications

Results (2217)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety results from IMblaze370, a randomised phase III study comparing atezolizumab + cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer
    Meeting Abstract

    Bendell, J.; Ciardiello, F.; Tabernero, J.; Tebbutt, N.; Eng, C.; Di Bartolomeo, M.; Falcone, A.; Fakih, M.; Kozloff, M.; Segal, N.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
    Meeting Abstract

    Tabernero, J.; Shitara, K.; Dvorkin, M.; Mansoor, W.; Arkenau, H. T.; Prokharau, A.; Alsina, M.; Ghidini, M.; Faustino, C.; Gorbunova, V.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Regorafenib Dose Optimization Study (ReDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for Regorafenib in refractory metastatic colorectal cancer (mCRC) - An ACCRU Network study
    Meeting Abstract

    Bekaii-Saab, T.; Ou, F.; Anderson, D.; Ahn, D.; Boland, P.; Ciombor, K.; Jacobs, N.; Desnoyers, R.; Cleary, J.; Meyers, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib plus MEK inhibitor binimetinib plus anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer
    Meeting Abstract

    Van Cutsem, E.; Cuyle, P.; Huijberts, S.; Schellens, J.; Elez, E.; Yaeger, R.; Fakih, M.; Montagut, C.; Peeters, M.; Desai, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Merle, P.; Rimassa, L.; Ryoo, B.; Cicin, I.; Harris, W.; Banu, E.; Sarker, D.; Tan, B.; Van Vlierberghe, H.; Sen, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Activity of larotrectinib in patients with TRK fusion GI malignancies
    Meeting Abstract

    Nathenson, M.; Demetri, G.; Lassen, U.; Hong, D.; Boni, V.; Deeken, J.; Dowlati, A.; Cox, M.; Ku, N.; Cruickshank, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • A phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585 - Trial in progress
    Meeting Abstract

    Bang, Y.; Van Cutsem, E.; Fuchs, C.; Ohtsu, A.; Tabernero, J.; Ilson, D.; Hyung, W.; Strong, V.; Goetze, T.; Yoshikawa, T.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress
    Meeting Abstract

    Cheng, A.; Abou-Alfa, G.; Ren, Z.; Assenat, E.; Cubillo, A.; Pluntke, S.; Rimassa, L.; Ross, P.; Wyrwicz, L.; Hou, J.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Treatment and testing patterns among patients with HER2+ advanced/metastatic gastric, esophageal or gastroesophageal junction (GEJ) adenocarcinoma in the United States
    Meeting Abstract

    Janjigian, Y.; Hess, L.; Zhu, Y.; Fang, Y.; Liepa, A.; Kuder, C.; Chin, S.
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability-high (MSI-H) colorectal cancer: KEYNOTE-164
    Meeting Abstract

    Le, D.; Kavan, P.; Kim, T.; Burge, M.; Van Cutsem, E.; Hara, H.; Boland, P.; Van Laethem, J.; Geva, R.; Taniguchi, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save